JNJ4796,2241664-16-2

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

JNJ4796

CAS No. : 2241664-16-2

MCE 国际站：JNJ4796

产品活性：JNJ4796 是具有口服活性的流感病毒融合性抑制剂，通过抑制血球凝集素 (HA) 介导的融合来中和甲型流感病毒。JNJ4796 和广泛中和抗体 (bnAbs) 的功能类似。

研究领域：Anti-infection

作用靶点：Influenza Virus

In Vitro: Like bnAb CR6261, the mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell.

In Vivo: Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD₅₀) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved.
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD₉₀), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival.

相关产品：Bioactive Compound Library Plus  |  Acetylcysteine  |  Tunicamycin  |  U0126-EtOH  |  Curcumin  |  Camptothecin  |  Vadimezan  |  Indomethacin  |  Molnupiravir  |  Aprotinin  |  Rifampicin  |  Baicalein  |  Oseltamivir acid  |  Geldanamycin  |  AEBSF hydrochloride  |  Spermine  |  α-Vitamin E  |  AG-1478  |  HA Peptide  |  Chlorogenic acid  |  YM-201636  |  Tofacitinib citrate  |  Favipiravir  |  Harringtonine  |  Baloxavir  |  Trimethoprim  |  SC75741  |  6-Diazo-5-oxo-L-nor-Leucine  |  GSK 650394  |  Isoliquiritigenin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds